Revenue Breakdown
Composition ()
No data
Revenue Streams
CareDx Inc (CDNA) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Testing Service revenue, accounting for 73.4% of total sales, equivalent to $60.81M. Other significant revenue streams include Digital and other revenue and Product revenue. Understanding this composition is critical for investors evaluating how CDNA navigates market cycles within the Biotechnology & Medical Research industry.
Profitability & Margins
Evaluating the bottom line, CareDx Inc maintains a gross margin of 67.24%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -5.57%, while the net margin is -3.79%. These profitability ratios, combined with a Return on Equity (ROE) of -6.27%, provide a clear picture of how effectively CDNA converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, CDNA competes directly with industry leaders such as BFLY and STAA. With a market capitalization of $960.05M, it holds a significant position in the sector. When comparing efficiency, CDNA's gross margin of 67.24% stands against BFLY's 55.71% and STAA's 82.21%. Such benchmarking helps identify whether CareDx Inc is trading at a premium or discount relative to its financial performance.
